LGALS3 and heart failure: During a 4-month follow-up period in the Valsartan Heart Failure Trial, there was a corresponding increase in the risk of mortality, primary morbid event, and hospitalization for heart failure (2.9, 2.1, and 2.2%, respectively) for every 1 μg/L increase in Gal-3 [40].